Items where Author is "Atmaca-Dirik, H."
 | Up a level |
Group by: Item Type | No Grouping
Jump to: Conference or Workshop Item
Number of items: 1.
Conference or Workshop Item
Wehler, T. and Wehler, B. and Atmaca-Dirik, H. and Schulz, C. and Grohe, C. and Topsch, J. and Ehrlich, A. (2021) Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC. In: European Lung Cancer Virtual Congress ELCC 2021, 25 March 2021 - 27 March 2021, Virtual.
